AstraZeneca announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the global rights to MEDI2070.
MEDI2070 is an IL-23 monoclonal antibody currently in a phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for phase II for ulcerative colitis, diseases that sit outside AstraZeneca’s three main therapy areas.
{iframe}http://www.pharmabiz.com/NewsDetails.aspx?aid=98740&sid=2{/iframe}